# AbbVie Dividend King Standout?

> AbbVie's 54-year dividend streak and patent resilience make it a top pick for income-focused investors despite industry risks.
- Title: AbbVie Dividend King Standout? · Yahoo Finance | Shortify
- Summary: AbbVie's 54-year dividend streak and patent resilience make it a top pick for income-focused investors despite industry risks. AbbVie maintains strong…
- Keywords: abbvie, dividend king, humira, patent cliff, allergan, rinvoq, skyrizi, nfl, seahawks, seattle, business, finance
- Source: Yahoo Finance — https://finance.yahoo.com/markets/stocks/articles/abbvie-best-dividend-king-buy-142000637.html
- Published: 2026-09-16T14:20:00+00:00
- Read time: 1 min
- Topics: abbvie, dividend king, humira, patent cliff, allergan, rinvoq, skyrizi, nfl, seahawks, seattle, business, finance
## 54-Year Dividend Streak
AbbVie has raised dividends for 54 consecutive years since splitting from Abbott Laboratories in 2013.

> Including the time AbbVie spent under the wing of its former parent company, it has increased its payouts for 54 consecutive years.
## Humira Patent Cliff Impact
Humira lost U.S. patent exclusivity in 2023, but AbbVie quickly rebounded with revenue growth through new products.

> This immunology medicine lost patent exclusivity in the U.S. in 2023.
## Allergan Acquisition
AbbVie's $63 billion acquisition of Allergan added Botox and other key products to its portfolio.

> The company's biggest deal was the $63 billion acquisition of Allergan, which granted it access to several key products, including the Botox franchise.
## Rinvoq and Skyrizi Growth
Rinvoq and Skyrizi are AbbVie's fastest-growing immunology products with patent exclusivity extending through the 2030s.

> These two immunology products are now its biggest growth drivers.
## Future Drug Pipeline
AbbVie has promising candidates like ABBV-295 for weight loss and ABBV-706 for cancer in late-stage trials.

> Acquired products, such as Zumilokibart, a promising investigational medicine for eczema, could meaningfully contribute down the line if they succeed in phase 3 studies.
## Dividend King Debate
Some investors avoid pharmaceuticals due to patent cliffs and regulatory risks, but AbbVie's track record shows resilience.

> For these people, a drugmaker like AbbVie is out of the question, regardless of how well it is performing right now.
## Stock Advisor Note
The Motley Fool's Stock Advisor team did not recommend AbbVie despite its strong dividend history.

> The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them.
## Key takeaway

AbbVie maintains strong dividend growth and innovation pipeline after Humira patent loss, offering reliable income with long-term resilience.